25 related articles for article (PubMed ID: 16380259)
1. Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells.
Song P; Zhao F; Li D; Qu J; Yao M; Su Y; Wang H; Zhou M; Wang Y; Gao Y; Li F; Zhao D; Zhang F; Rao Y; Xia M; Li H; Wang J; Cheng M
Acta Pharm Sin B; 2022 Jun; 12(6):2905-2922. PubMed ID: 35755272
[TBL] [Abstract][Full Text] [Related]
2. Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Jha V; Macchia M; Tuccinardi T; Poli G
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32824733
[TBL] [Abstract][Full Text] [Related]
3. Insights into the EGFR SAR of N-phenylquinazolin-4-amine-derivatives using quantum mechanical pairwise-interaction energies.
Simeon S; Jongkon N; Chotpatiwetchkul W; Gleeson MP
J Comput Aided Mol Des; 2019 Aug; 33(8):745-757. PubMed ID: 31494804
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis and Biological Evaluation of Isoxazole-Based CK1 Inhibitors Modified with Chiral Pyrrolidine Scaffolds.
Luxenburger A; Schmidt D; Ianes C; Pichlo C; Krüger M; von Drathen T; Brunstein E; Gainsford GJ; Baumann U; Knippschild U; Peifer C
Molecules; 2019 Mar; 24(5):. PubMed ID: 30832206
[TBL] [Abstract][Full Text] [Related]
5. Role of the Fyn-PKCδ signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Sharma S; Carlson S; Puttachary S; Sarkar S; Showman L; Putra M; Kanthasamy AG; Thippeswamy T
Neurobiol Dis; 2018 Feb; 110():102-121. PubMed ID: 29197620
[TBL] [Abstract][Full Text] [Related]
6. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives.
Asif M
Int J Med Chem; 2014; 2014():395637. PubMed ID: 25692041
[TBL] [Abstract][Full Text] [Related]
7. Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
Barlaam B; Anderton J; Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Kettle JG; Kirk G; Klinowska T; Lambert-van der Brempt C; Trigwell C; Vincent J; Ogilvie D
ACS Med Chem Lett; 2013 Aug; 4(8):742-6. PubMed ID: 24900741
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of quinazolines as tyrosine kinase inhibitors.
Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines.
Wakeling AE; Barker AJ; Davies DH; Brown DS; Green LR; Cartlidge SA; Woodburn JR
Breast Cancer Res Treat; 1996; 38(1):67-73. PubMed ID: 8825124
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor.
Smaill JB; Palmer BD; Rewcastle GW; Denny WA; McNamara DJ; Dobrusin EM; Bridges AJ; Zhou H; Showalter HD; Winters RT; Leopold WR; Fry DW; Nelson JM; Slintak V; Elliot WL; Roberts BJ; Vincent PW; Patmore SJ
J Med Chem; 1999 May; 42(10):1803-15. PubMed ID: 10346932
[TBL] [Abstract][Full Text] [Related]
14. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors. 13. Structure-activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
Thompson AM; Murray DK; Elliott WL; Fry DW; Nelson JA; Showalter HD; Roberts BJ; Vincent PW; Denny WA
J Med Chem; 1997 Nov; 40(24):3915-25. PubMed ID: 9397172
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
